Hongjing has led the CAR T therapy development spanning ex vivo autologous and allogeneic CAR T, in vivo mRNA LNP CAR T, and now focus on next generation delivery technologies targeting autoimmune and…
Is this you? Claim this profile →
No public contact links on file.
Speaking history
Sectors
Sourcing speakers for your event?
Browse the speaker directory →